Hepion net loss widens to $1.25 million in Q2 2026; revenue flat at no revenue
HEPA•Q2 2026 financial results
- Hepion posted a net loss of USD 1.25 million for the quarter ended June 30, 2026, widening from USD 1.04 million.
- Operating loss narrowed to USD 1.21 million from USD 1.75 million, on lower operating expenses of USD 1.21 million.
- General and administrative costs rose to USD 1.16 million from USD 919,488, while research and development spending fell to USD 50,918 from USD 423,277.
- No revenue was reported, while a USD 42,989 warrant fair-value loss replaced a USD 698,073 gain a year earlier.
Strategy shifts toward diagnostics
- Strategy shifted toward diagnostics, including a Cirna Diagnostics license with USD 70,000 paid upfront and potential milestones up to USD 6.85 million.
